Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives from 2 Pathologists

Gastroenterology

Volumn 149, Issue 6, 2015, Pages 1305-1308

  Kleiner, David E ^a   Bedossa, Pierre ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; OBETICHOLIC ACID; PIOGLITAZONE;

CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; NOTE; PATHOLOGIST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BIOPSY; CLASSIFICATION; CLINICAL PRACTICE; DISEASE COURSE; FATTY LIVER; FIBROSIS; INFLAMMATION; LIVER; LIVER CELL; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; STANDARDS;

BIOPSY; DISEASE PROGRESSION; FATTY LIVER; FIBROSIS; HEPATOCYTES; HUMANS; INFLAMMATION; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY, CLINICAL; PRACTICE PATTERNS, PHYSICIANS';

EID: 84945539188     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.09.015     Document Type: Editorial

References (26)

1. J.A. Marrero, R.J. Fontana, G.L. Su, and et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States Hepatology 36 2002 1349 1354
2. A. Sanyal, A. Poklepovic, E. Moyneur, and et al. Population-based risk factors and resource utilization for HCC: US perspective Curr Med Res Opin 26 2010 2183 2191
3. A.J. Sanyal, E.M. Brunt, D.E. Kleiner, and et al. End points and clinical trial design for nonalcoholic steatohepatitis Hepatology 54 2011 344 353
4. D.E. Kleiner, E.M. Brunt, M. Van Natta, and et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
5. A.J. Sanyal, S.L. Friedman, A.J. McCullough, and et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop Hepatology 61 2015 1392 1405
6. P. Bedossa, C. Poitou, N. Veyrie, and et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients Hepatology 56 2012 1751 1759
7. E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, and et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 94 1999 2467 2474
8. A.J. Sanyal, N. Chalasani, K.V. Kowdley, and et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
9. B.A. Neuschwander-Tetri, R. Loomba, A.J. Sanyal, and et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 385 2015 956 965
10. L.A. Adams, and V. Ratziu Non-alcoholic fatty liver - perhaps not so benign J Hepatol 62 2015 1002 1004
11. J. Ludwig, T.R. Viggiano, D.B. McGill, and et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease Mayo Clin Proc 55 1980 434 438
12. B.R. Bacon, M.J. Farahvash, C.G. Janney, and et al. Nonalcoholic steatohepatitis: an expanded clinical entity Gastroenterology 107 1994 1103 1109
13. R.G. Lee Nonalcoholic steatohepatitis: a study of 49 patients Hum Pathol 20 1989 594 598
14. E.E. Powell, W.G. Cooksley, R. Hanson, and et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years Hepatology 11 1990 74 80
15. C. Carter-Kent, L.M. Yerian, E.M. Brunt, and et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study Hepatology 50 2009 1113 1120
16. J.B. Schwimmer, C. Behling, R. Newbury, and et al. Histopathology of pediatric nonalcoholic fatty liver disease Hepatology 42 2005 641 649
17. D.E. Kleiner, and E.M. Brunt Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research Semin Liver Dis 32 2012 3 13
18. B.A. Neuschwander-Tetri, J.M. Clark, N.M. Bass, and et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease Hepatology 52 2010 913 924
19. S. McPherson, T. Hardy, E. Henderson, and et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management J Hepatol 62 2015 1148 1155
20. R. Pais, F. Charlotte, L. Fedchuk, and et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver J Hepatol 59 2013 550 556
21. G. Lutchman, A. Modi, D.E. Kleiner, and et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis Hepatology 46 2007 424 429
22. P. Bedossa Consortium FP Utility and appropriateness of the Fatty Liver Inhibition of Progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease Hepatology 60 2014 565 575
23. P. Angulo, D.E. Kleiner, S. Dam-Larsen, and et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease Gastroenterology 149 2015 389 397
24. Z.M. Younossi, M. Stepanova, N. Rafiq, and et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality Hepatology 53 2011 1874 1882
25. M. Ekstedt, H. Hagstrom, P. Nasr, and et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology 61 2015 1547 1554
26. Z.D. Goodman, R.L. Becker Jr., P.J. Pockros, and et al. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis Hepatology 45 2007 886 894